These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26611352)

  • 21. Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats.
    Badawi GA; Abd El Fattah MA; Zaki HF; El Sayed MI
    Neurotox Res; 2019 Apr; 35(3):635-653. PubMed ID: 30673988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unmasking the Effects of L-DOPA on Rapid Dopamine Signaling with an Improved Approach for Nafion Coating Carbon-Fiber Microelectrodes.
    Qi L; Thomas E; White SH; Smith SK; Lee CA; Wilson LR; Sombers LA
    Anal Chem; 2016 Aug; 88(16):8129-36. PubMed ID: 27441547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
    Alvarsson A; Zhang X; Stan TL; Schintu N; Kadkhodaei B; Millan MJ; Perlmann T; Svenningsson P
    J Neurosci; 2015 Oct; 35(41):14057-69. PubMed ID: 26468205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats.
    Conti MM; Meadows SM; Melikhov-Sosin M; Lindenbach D; Hallmark J; Werner DF; Bishop C
    Neuropharmacology; 2016 Nov; 110(Pt A):125-134. PubMed ID: 27452719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
    Lindenbach D; Dupre KB; Eskow Jaunarajs KL; Ostock CY; Goldenberg AA; Bishop C
    Brain Res; 2013 Nov; 1537():327-39. PubMed ID: 24060645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
    Kuo TT; Chen YH; Wang V; Huang EY; Ma KH; Greig NH; Jung J; Choi HI; Olson L; Hoffer BJ; Tseng KY
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Striatal serotonin transporter gain-of-function in L-DOPA-treated, hemi-parkinsonian rats.
    Conti Mazza MM; Centner A; Werner DF; Bishop C
    Brain Res; 2023 Jul; 1811():148381. PubMed ID: 37127174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms.
    Robertson GS; Robertson HA
    J Neurosci; 1989 Sep; 9(9):3326-31. PubMed ID: 2795165
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
    Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of tricyclic antidepressants on L-DOPA-induced dyskinesia and motor improvement in hemi-parkinsonian rats.
    Conti MM; Goldenberg AA; Kuberka A; Mohamed M; Eissa S; Lindenbach D; Bishop C
    Pharmacol Biochem Behav; 2016 Mar; 142():64-71. PubMed ID: 26791104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA.
    Lorenc-Koci E; Czarnecka A; Lenda T; Kamińska K; Konieczny J
    Neurochem Int; 2013 Dec; 63(8):790-804. PubMed ID: 24090640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L-DOPA in the rat striatum.
    Gołembiowska K; Dziubina A; Kowalska M; Kamińska K
    Pharmacol Rep; 2008; 60(3):319-30. PubMed ID: 18622056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
    Porras G; De Deurwaerdere P; Li Q; Marti M; Morgenstern R; Sohr R; Bezard E; Morari M; Meissner WG
    Sci Rep; 2014 Jan; 4():3730. PubMed ID: 24429495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease.
    Navailles S; Bioulac B; Gross C; De Deurwaerdère P
    Neurobiol Dis; 2011 Feb; 41(2):585-90. PubMed ID: 21092759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
    El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
    Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
    Barnum CJ; Eskow KL; Dupre K; Blandino P; Deak T; Bishop C
    Neuroscience; 2008 Sep; 156(1):30-41. PubMed ID: 18687386
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapamycin, by Inhibiting mTORC1 Signaling, Prevents the Loss of Striatal Bidirectional Synaptic Plasticity in a Rat Model of L-DOPA-Induced Dyskinesia.
    Calabrese V; Di Maio A; Marino G; Cardinale A; Natale G; De Rosa A; Campanelli F; Mancini M; Napolitano F; Avallone L; Calabresi P; Usiello A; Ghiglieri V; Picconi B
    Front Aging Neurosci; 2020; 12():230. PubMed ID: 32848709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine Dysregulation and Altered Responses to Drugs Affecting Dopaminergic Transmission in a New Dopamine Transporter Knockout (DAT-KO) Rat Model.
    Lloyd JT; Yee AG; Kalligappa PK; Jabed A; Cheung PY; Todd KL; Karunasinghe RN; Vlajkovic SM; Freestone PS; Lipski J
    Neuroscience; 2022 May; 491():43-64. PubMed ID: 35331847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.